Amount$35M
Post-money valuation$233M
SeriesSeries F
AnnouncedAug 19, 2014
SectorLife Sciences
Solid
A solid round with healthy fundamentals.
Round size vs peers
Smaller than the typical Series F round.
Syndicate size
Single investor — limited external validation.
Insider conviction
1 existing investor re-upped — insiders doubling down.
Investor track record
A mix of established and emerging investors.
Heuristic read of round size vs peers, syndicate size, insider conviction, and investor track record. Not investment advice.
vs. Series F rounds (255)
Round size distribution7th pct
smaller Series F roundslarger
Post-money valuation1th pct
$200Mthis round: $233M$15B
